Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study

Trial Profile

Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Aug 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eltrombopag (Primary) ; Immune globulin
  • Indications Idiopathic thrombocytopenic purpura
  • Focus Therapeutic Use
  • Acronyms BRIDGING ITP
  • Most Recent Events

    • 12 Aug 2019 Planned End Date changed from 1 Sep 2019 to 1 Dec 2019.
    • 07 Mar 2019 Planned End Date changed from 1 Jan 2019 to 1 Sep 2019.
    • 07 Mar 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top